ArticleDiagnostics (Basel, Switzerland)2022
Embedded AMIS-Deep Learning with Dialog-Based Object Query System for Multi-Class Tuberculosis Drug Response Classification.
Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 12 citations in OpenAlex.
- Computer-aided diagnosis using embedded ensemble deep learning for multiclass drug-resistant tuberculosis classification.Frontiers in medicine · 2023Article
- Drug-Resistant Tuberculosis Treatment Recommendation, and Multi-Class Tuberculosis Detection and Classification Using Ensemble Deep Learning-Based System.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A person infected with drug-resistant tuberculosis (DR-TB) is the one who does not respond to typical TB treatment. DR-TB necessitates a longer treatment period and a more difficult treatment protocol. In addition, it can spread and infect individuals in the same manner as regular TB, despite the fact that early detection of DR-TB could reduce the cost and length of TB treatment. This study provided a fast and effective classification scheme for the four subtypes of TB: Drug-sensitive tuberculosis (DS-TB), drug-resistant tuberculosis (DR-TB), multidrug-resistant tuberculosis (MDR-TB), and extensively drug-resistant tuberculosis (XDR-TB). The drug response classification system (DRCS) has been developed as a classification tool for DR-TB subtypes. As a classification method, ensemble deep learning (EDL) with two types of image preprocessing methods, four convolutional neural network (CNN) architectures, and three decision fusion methods have been created. Later, the model developed by EDL will be included in the dialog-based object query system (DBOQS), in order to enable the use of DRCS as the classification tool for DR-TB in assisting medical professionals with diagnosing DR-TB. EDL yields an improvement of 1.17-43.43% over the existing methods for classifying DR-TB, while compared with classic deep learning, it generates 31.25% more accuracy. DRCS was able to increase accuracy to 95.8% and user trust to 95.1%, and after the trial period, 99.70% of users were interested in continuing the utilization of the system as a supportive diagnostic tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.